Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …

Background PIK3CA mutations occur in approximately 40% of patients with hormone
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …

Background Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …

Estrogen receptor alpha (ERα) is a well-established therapeutic target for the treatment of
ER-positive (ER+) breast cancers. Despite the tremendous successes achieved with …

Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide
3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize …